Mostrar registro simples

dc.contributor.authorCastilhos, Raphael Machado dept_BR
dc.contributor.authorBlank, Deborahpt_BR
dc.contributor.authorNetto, Cristina Brinckmann Oliveirapt_BR
dc.contributor.authorSouza, Carolina Fischinger Moura dept_BR
dc.contributor.authorFernandes, Luiz Nelson Teixeirapt_BR
dc.contributor.authorSchwartz, Ida Vanessa Doederleinpt_BR
dc.contributor.authorGiugliani, Robertopt_BR
dc.contributor.authorJardim, Laura Bannachpt_BR
dc.date.accessioned2014-02-26T01:51:31Zpt_BR
dc.date.issued2012pt_BR
dc.identifier.issn0100-879Xpt_BR
dc.identifier.urihttp://hdl.handle.net/10183/87727pt_BR
dc.description.abstractProgressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data for JOA in these diseases. A new scale, Severity Score System for Progressive Myelopathy (SSPROM), was constructed covering motor disability, sphincter dysfunction, spasticity, and sensory losses. Inter- and intra-rater reliabilities were measured. External validation was tested by applying JOA, the Expanded Disability Status Scale (EDSS), the Barthel index, and the Osame Motor Disability Score. Thirty-eight patients, 17 with adrenomyeloneuropathy, 3 with mucopolysaccharidosis I, 3 with mucopolysaccharidosis IV, 2 with mucopolysaccharidosis VI, 2 with mucolipidosis, and 11 with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy participated in the study. The mean ± SD SSPROM and JOA scores were 74.6 ± 11.4 and 12.4 ± 2.3, respectively. Construct validity for SSPROM (JOA: r = 0.84, P < 0.0001; EDSS: r = -0.83, P < 0.0001; Barthel: r = 0.56, P < 0.002; Osame: r = -0.94, P < 0.0001) and reliability (intra-rater: r = 0.83, P < 0.0001; inter-rater: r = 0.94, P < 0.0001) were demonstrated. The metric properties of JOA were similar to those found in SSPROM. Several clinimetric requirements were met for both SSPROM and JOA scales. Since SSPROM has a wider range, it should be useful for follow-up studies on IEM myelopathies.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofRevista brasileira de pesquisas médicas e biológicas = Brazilian journal of medical and biological research. Ribeirão Preto, SP. Vol. 45, n. 7 (July 2012), p. 565-572pt_BR
dc.rightsOpen Accessen
dc.subjectJapanese Orthopaedic Associationen
dc.subjectMucopolissacaridosept_BR
dc.subjectSeverity Score System for Progressive Myelopathyen
dc.subjectMucolipidosespt_BR
dc.subjectMucopolysaccharidosisen
dc.subjectMucolipidosisen
dc.subjectAdrenomyeloneuropathyen
dc.subjectProgressive myelopathiesen
dc.titleSeverity score system for progressive myelopathy : development and validation of a new clinical scalept_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000856369pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples